FR09C0050I1 - - Google Patents

Info

Publication number
FR09C0050I1
FR09C0050I1 FR09C0050C FR09C0050I1 FR 09C0050 I1 FR09C0050 I1 FR 09C0050I1 FR 09C0050 C FR09C0050 C FR 09C0050C FR 09C0050 I1 FR09C0050 I1 FR 09C0050I1
Authority
FR
France
Prior art keywords
pharmacologically active
protein
absence
active agent
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24895164&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR09C0050(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Publication of FR09C0050I1 publication Critical patent/FR09C0050I1/fr
Application filed filed Critical
Application granted granted Critical
Publication of FR09C0050I2 publication Critical patent/FR09C0050I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/927—Diagnostic contrast agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Pediatric Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
FR09C0050C 1996-10-01 2009-10-06 Agents pharmaceutiquement actifs stabilises par proteine et leur utilisation Active FR09C0050I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/720,756 US5916596A (en) 1993-02-22 1996-10-01 Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
PCT/US1997/017157 WO1998014174A1 (fr) 1996-10-01 1997-09-24 Agents pharmaceutiquement actifs stabilises par proteine, procedes de preparation et procedes d'utilisation

Publications (2)

Publication Number Publication Date
FR09C0050I1 true FR09C0050I1 (fr) 2009-06-11
FR09C0050I2 FR09C0050I2 (fr) 2012-06-22

Family

ID=24895164

Family Applications (1)

Application Number Title Priority Date Filing Date
FR09C0050C Active FR09C0050I2 (fr) 1996-10-01 2009-10-06 Agents pharmaceutiquement actifs stabilises par proteine et leur utilisation

Country Status (19)

Country Link
US (1) US5916596A (fr)
EP (3) EP2286798A1 (fr)
JP (2) JP4837809B2 (fr)
CN (2) CN1515244B (fr)
AT (1) ATE427739T1 (fr)
AU (1) AU718753B2 (fr)
BR (2) BRPI9715297B8 (fr)
CA (2) CA2267498C (fr)
DE (2) DE69739348D1 (fr)
DK (1) DK0961612T4 (fr)
ES (2) ES2609853T3 (fr)
FR (1) FR09C0050I2 (fr)
HK (1) HK1024866A1 (fr)
LU (1) LU91613I2 (fr)
NL (1) NL300417I1 (fr)
NO (1) NO328689B1 (fr)
NZ (1) NZ335133A (fr)
PT (1) PT961612E (fr)
WO (1) WO1998014174A1 (fr)

Families Citing this family (325)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US6749868B1 (en) * 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US20030068362A1 (en) * 1993-02-22 2003-04-10 American Bioscience, Inc. Methods and formulations for the delivery of pharmacologically active agents
US20070117863A1 (en) * 1993-02-22 2007-05-24 Desai Neil P Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
EP0693924B2 (fr) * 1993-02-22 2008-04-09 Abraxis BioScience, Inc. Procedes d'administration (in vivo) de substances biologiques et compositions utilisees dans ces procedes
US20030133955A1 (en) * 1993-02-22 2003-07-17 American Bioscience, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US6537579B1 (en) * 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US6753006B1 (en) 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US6774278B1 (en) 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
US6143211A (en) * 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
US8137684B2 (en) 1996-10-01 2012-03-20 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20030203036A1 (en) 2000-03-17 2003-10-30 Gordon Marc S. Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
GB9703673D0 (en) * 1997-02-21 1997-04-09 Bradford Particle Design Ltd Method and apparatus for the formation of particles
US20030199425A1 (en) * 1997-06-27 2003-10-23 Desai Neil P. Compositions and methods for treatment of hyperplasia
US8853260B2 (en) * 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
KR101180181B1 (ko) * 1997-06-27 2012-09-05 아브락시스 바이오사이언스, 엘엘씨 나노 입자 및 그의 제조 방법
KR100789008B1 (ko) * 1997-06-27 2007-12-26 아브락시스 바이오사이언스 인크. 신규 약물 제제
DE69841984D1 (de) * 1997-09-05 2010-12-16 Maruho K K Zusammensetzung aus nanokapseln zur behandlung von intraarticulaeren erkrankungen
HUP9701554D0 (en) * 1997-09-18 1997-11-28 Human Oltoanyagtermeloe Gyogys Pharmaceutical composition containing plazma proteins
US6884842B2 (en) 1997-10-14 2005-04-26 Alnis Biosciences, Inc. Molecular compounds having complementary surfaces to targets
US20030059465A1 (en) * 1998-05-11 2003-03-27 Unger Evan C. Stabilized nanoparticle formulations of camptotheca derivatives
AU5241199A (en) * 1998-07-30 2000-02-21 Novopharm Biotech Inc. Pharmaceutically acceptable composition comprising an aqueous solution of paclitaxel and albumin
GB9820746D0 (en) † 1998-09-23 1998-11-18 Pharmax Limited Micronised pharmaceutical compositions
US20040013613A1 (en) * 2001-05-18 2004-01-22 Jain Rajeev A Rapidly disintegrating solid oral dosage form
US8236352B2 (en) * 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
EP1117384A1 (fr) * 1998-10-01 2001-07-25 Elan Pharma International Limited Liberation regulee de compositions nanoparticulaires
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
AT406054B (de) * 1998-11-04 2000-02-25 Andreas Bernkop-Schnuerch Verfahren zur verbesserung der mucoadhäsion von polymeren sowie deren herstellung und verwendung
US6428814B1 (en) * 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US7521068B2 (en) * 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
US20040141925A1 (en) * 1998-11-12 2004-07-22 Elan Pharma International Ltd. Novel triamcinolone compositions
DE19856432A1 (de) * 1998-12-08 2000-06-15 Basf Ag Nanopartikuläre Kern-Schale Systeme sowie deren Verwendung in pharmazeutischen und kosmetischen Zubereitungen
DE19919769A1 (de) 1999-04-30 2000-11-02 Henkel Kgaa Verwendung nanoskaliger antimikrobieller Wirkstoffe in Körperdeodorantien
GB9910975D0 (en) * 1999-05-13 1999-07-14 Univ Strathclyde Rapid dehydration of proteins
CA2371912C (fr) * 1999-05-21 2010-02-16 American Bioscience, Inc. Agents a stabilisation proteinique actifs pharmacologiquement; procedes de fabrication et methodes d'utilisation
GB2350297A (en) * 1999-05-27 2000-11-29 Abbott Lab Injectable halogenated anesthetic formulation in emulsion form
US7919119B2 (en) * 1999-05-27 2011-04-05 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6610317B2 (en) 1999-05-27 2003-08-26 Acusphere, Inc. Porous paclitaxel matrices and methods of manufacture thereof
US20040115134A1 (en) * 1999-06-22 2004-06-17 Elan Pharma International Ltd. Novel nifedipine compositions
US20090104273A1 (en) * 1999-06-22 2009-04-23 Elan Pharma International Ltd. Novel nifedipine compositions
DE19932157A1 (de) * 1999-07-13 2001-01-18 Pharmasol Gmbh Verfahren zur schonenden Herstellung von hochfeinen Mikropartikeln und Nanopartikeln
US6656504B1 (en) 1999-09-09 2003-12-02 Elan Pharma International Ltd. Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions
CA2388676A1 (fr) * 1999-10-13 2001-04-19 Chiron Corporation Procede d'obtention de reponses immunes cellulaires de proteines
US20040009229A1 (en) * 2000-01-05 2004-01-15 Unger Evan Charles Stabilized nanoparticle formulations of camptotheca derivatives
US20020041898A1 (en) * 2000-01-05 2002-04-11 Unger Evan C. Novel targeted delivery systems for bioactive agents
JP2003520210A (ja) * 2000-01-05 2003-07-02 イマレックス セラピューティクス， インコーポレイテッド 低い水溶性を有する薬物の送達のための薬学的処方物
GB2359747B (en) * 2000-02-29 2002-04-24 Maelor Pharmaceuticals Ltd Anaesthetic formulations
AU2001245947A1 (en) * 2000-03-23 2001-10-03 Collaborative Technologies, Inc Method for preparing high pressure/high shear dispersions containing physiologically active ingredients
ITMI20001107A1 (it) * 2000-05-18 2001-11-18 Acs Dobfar Spa Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel
US20040156872A1 (en) * 2000-05-18 2004-08-12 Elan Pharma International Ltd. Novel nimesulide compositions
DE10036871A1 (de) * 2000-07-28 2002-02-14 Pharmasol Gmbh Dispersionen zur Formulierung wenig oder schwer löslicher Wirkstoffe
US6623765B1 (en) 2000-08-01 2003-09-23 University Of Florida, Research Foundation, Incorporated Microemulsion and micelle systems for solubilizing drugs
US7198795B2 (en) 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
US6541030B2 (en) 2000-09-27 2003-04-01 Verion Inc. Instant water dissolvable encapsulate and process
CA2420552A1 (fr) * 2000-10-02 2002-04-11 Kimberly-Clark Worldwide, Inc. Encres a base de nanoparticules et procede de fabrication
US7803149B2 (en) * 2002-07-12 2010-09-28 Cook Incorporated Coated medical device
IL155696A0 (en) 2000-11-09 2003-11-23 Neopharm Inc Sn-38 lipid complexes and methods of use
GB0027357D0 (en) 2000-11-09 2000-12-27 Bradford Particle Design Plc Particle formation methods and their products
US6869617B2 (en) * 2000-12-22 2005-03-22 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US6977085B2 (en) * 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US20050048126A1 (en) * 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US20030096013A1 (en) * 2000-12-22 2003-05-22 Jane Werling Preparation of submicron sized particles with polymorph control
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US20040256749A1 (en) * 2000-12-22 2004-12-23 Mahesh Chaubal Process for production of essentially solvent-free small particles
US6951656B2 (en) * 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US6884436B2 (en) 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US9700866B2 (en) * 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US7193084B2 (en) * 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US7115565B2 (en) 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
US20040022861A1 (en) * 2001-01-30 2004-02-05 Williams Robert O. Process for production of nanoparticles and microparticles by spray freezing into liquid
US20030157170A1 (en) * 2001-03-13 2003-08-21 Richard Liggins Micellar drug delivery vehicles and precursors thereto and uses thereof
EP1418945A2 (fr) * 2001-03-13 2004-05-19 Angiotech Pharmaceuticals, Inc. Vecteurs de delivrance de medicament micellaires, leurs precurseurs et leurs utilisations
DE10115740A1 (de) * 2001-03-26 2002-10-02 Ulrich Speck Zubereitung für die Restenoseprophylaxe
CA2441108A1 (fr) * 2001-04-05 2002-10-17 Universite Laval Procede de fabrication d'une matrice d'administration et utilisations
DE60220519T2 (de) * 2001-04-20 2007-09-27 The University Of British Columbia, Vancouver Mizellares arzneistoffverabreichungssystem für hydrophobe arzneistoffe
SG126676A1 (en) * 2001-05-09 2007-01-30 Nanomaterials Tech Pte Ltd Process for the controlled production of organic particles
WO2003030864A1 (fr) * 2001-05-29 2003-04-17 Neopharm, Inc. Formulation liposomale d'irinotecan
CA2451187C (fr) 2001-06-22 2012-08-14 Southern Biosystems, Inc. Implants coaxiaux a liberation prolongee d'ordre 0
GB0116074D0 (en) * 2001-06-29 2001-08-22 Univ Strathclyde Nanoparticle structures
US20040013698A1 (en) * 2001-07-09 2004-01-22 Aust Duncan T Method for preparing topical preparations containing skin protective agents with enhanced barrier properties
TWI252847B (en) * 2001-07-10 2006-04-11 Synta Pharmaceuticals Corp Synthesis of taxol enhancers
TWI332943B (en) * 2001-07-10 2010-11-11 Synta Pharmaceuticals Corp Taxol enhancer compounds
TWI297335B (en) 2001-07-10 2008-06-01 Synta Pharmaceuticals Corp Taxol enhancer compounds
US20040018250A1 (en) * 2001-07-11 2004-01-29 Ceccoli Joseph D. Methods for preparing high pressure/high shear dispersions containing waxes and other semi-solids and oils
US6746635B2 (en) * 2001-08-08 2004-06-08 Brown University Research Foundation Methods for micronization of hydrophobic drugs
US20030199587A1 (en) * 2001-08-14 2003-10-23 Franz G. Andrew Levothyroxine compositions having unique Cmax properties
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
MXPA04002446A (es) * 2001-09-26 2004-07-23 Baxter Int Preparacion de nanoparticulas de tamano de submicras mediante dispersion y remocion de la fase liquida o solvente.
US20060003012A9 (en) * 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
JPWO2003034302A1 (ja) * 2001-10-15 2005-02-03 株式会社シュタルク コンテンツ配信用サーバ及びこれを備えたコンテンツ配信システム
ES2625340T3 (es) * 2001-10-15 2017-07-19 Crititech, Inc. Composiciones y métodos para la administración de fármacos escasamente solubles en agua y métodos de tratamiento
US7112340B2 (en) * 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
NZ531944A (en) 2001-10-19 2006-03-31 Isotechnika Inc Synthesis of cyclosporin analogs
WO2003037359A1 (fr) * 2001-10-29 2003-05-08 Chengdu Somo Namotechnology Co., Ltd. Nanoparticule de composants de medicaments insolubles et procede de production correspondant
US20040101566A1 (en) * 2002-02-04 2004-05-27 Elan Pharma International Limited Novel benzoyl peroxide compositions
PT1471887E (pt) 2002-02-04 2010-07-16 Elan Pharma Int Ltd ComposiãŽes de nanopartculas com lisozima como um estabilizador superficial
WO2003080027A1 (fr) * 2002-03-20 2003-10-02 Elan Pharma International, Ltd. Compositions nanoparticulaires d'inhibiteurs d'angiogenese
US20080220075A1 (en) * 2002-03-20 2008-09-11 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
US20040076586A1 (en) * 2002-03-28 2004-04-22 Reinhard Koening Compositions and methods for delivering pharmaceutically active agents using nanoparticulates
ITMI20020681A1 (it) * 2002-03-29 2003-09-29 Acs Dobfar Spa Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina
ITMI20020680A1 (it) * 2002-03-29 2003-09-29 Acs Dobfar Spa Composizione antitumorale migliorata a base di paclitaxel e metodo per il suo ottenimento
US20040082521A1 (en) * 2002-03-29 2004-04-29 Azaya Therapeutics Inc. Novel formulations of digitalis glycosides for treating cell-proliferative and other diseases
AU2003263024A1 (en) * 2002-04-23 2003-11-10 Christopher Mcconville Process of forming and modifying particles and compositions produced thereby
GB0216562D0 (en) 2002-04-25 2002-08-28 Bradford Particle Design Ltd Particulate materials
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
CA2491312C (fr) * 2002-07-15 2011-05-31 Alcon, Inc. Film bioeroable pour l'administration de medicaments ophtalmiques
WO2004006959A1 (fr) * 2002-07-16 2004-01-22 Elan Pharma International, Ltd Compositions pour doses liquides d'agents actifs nanoparticulaires stables
GB0216700D0 (en) 2002-07-18 2002-08-28 Astrazeneca Ab Process
DE10234165B4 (de) * 2002-07-26 2008-01-03 Advanced Micro Devices, Inc., Sunnyvale Verfahren zum Füllen eines Grabens, der in einem Substrat gebildet ist, mit einem isolierenden Material
BR0313428A (pt) * 2002-08-12 2005-06-28 Pfizer Prod Inc Composições farmacêuticas de drogas semi-ordenados e polìmeros
US20060030578A1 (en) * 2002-08-20 2006-02-09 Neopharm, Inc. Pharmaceutically active lipid based formulation of irinotecan
WO2004035032A2 (fr) * 2002-08-20 2004-04-29 Neopharm, Inc. Formulation de sn-38 a base de lipides pharmaceutiquement actifs
US7090868B2 (en) * 2002-09-13 2006-08-15 University Of Florida Materials and methods for drug delivery and uptake
US20050051922A1 (en) * 2002-09-20 2005-03-10 Avinash Nangia Pharmaceutical composition with sodium lauryl sulfate as an extra-granular absorption/compression enhancer and the process to make the same
DE10244847A1 (de) 2002-09-20 2004-04-01 Ulrich Prof. Dr. Speck Medizinische Vorrichtung zur Arzneimittelabgabe
WO2004032947A1 (fr) * 2002-10-09 2004-04-22 Unibioscreen S.A. Extrait ayant un action antitumoral et antitoxique
EP1556011A1 (fr) * 2002-10-28 2005-07-27 Polymerix Corporation Compositions therapeutiques
JP2006514698A (ja) * 2002-10-30 2006-05-11 スフェリックス， インコーポレイテッド ナノ粒子生物活性物質
CA2505520C (fr) * 2002-11-06 2012-07-17 Azaya Therapeutics, Inc. Preparations liposomales d'agents pharmaceutiques stabilisees par des proteines
WO2004045494A2 (fr) * 2002-11-20 2004-06-03 Bar-Ilan University Colle biologique a base de nanoparticules conjugues de thrombine
RU2361615C2 (ru) * 2002-12-09 2009-07-20 Абраксис Байосайенс, Ллс. Композиции и способы доставки фармакологических агентов
KR20140148502A (ko) * 2002-12-09 2014-12-31 아브락시스 바이오사이언스, 엘엘씨 약리학적 물질의 조성물 및 그 전달방법
KR20200083657A (ko) * 2002-12-09 2020-07-08 아브락시스 바이오사이언스, 엘엘씨 약리학적 물질의 조성물 및 그 전달방법
US6780896B2 (en) * 2002-12-20 2004-08-24 Kimberly-Clark Worldwide, Inc. Stabilized photoinitiators and applications thereof
US8409618B2 (en) 2002-12-20 2013-04-02 Kimberly-Clark Worldwide, Inc. Odor-reducing quinone compounds
US7666410B2 (en) 2002-12-20 2010-02-23 Kimberly-Clark Worldwide, Inc. Delivery system for functional compounds
TWI330079B (en) * 2003-01-15 2010-09-11 Synta Pharmaceuticals Corp Treatment for cancers
ATE354380T1 (de) * 2003-02-03 2007-03-15 Polaschegg Hans-Dietrich Dr Te Zusammensetzung zur prävention von infektionen durch subkutane prothesen
GB0302673D0 (en) 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
US7968115B2 (en) 2004-03-05 2011-06-28 Board Of Regents, The University Of Texas System Liposomal curcumin for treatment of cancer
WO2004080396A2 (fr) * 2003-03-07 2004-09-23 The University Of Texas Md Anderson Cancer Center Curcumine liposomale pour traiter le cancer
US20040225022A1 (en) * 2003-05-09 2004-11-11 Desai Neil P. Propofol formulation containing reduced oil and surfactants
US20040247624A1 (en) * 2003-06-05 2004-12-09 Unger Evan Charles Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility
US8476010B2 (en) * 2003-07-10 2013-07-02 App Pharmaceuticals Llc Propofol formulations with non-reactive container closures
US20050181018A1 (en) * 2003-09-19 2005-08-18 Peyman Gholam A. Ocular drug delivery
WO2005030169A1 (fr) * 2003-10-02 2005-04-07 Sembiosys Genetics Inc. Procedes pour preparer des corps huileux comprenant des principes actifs
US7754197B2 (en) 2003-10-16 2010-07-13 Kimberly-Clark Worldwide, Inc. Method for reducing odor using coordinated polydentate compounds
US7678367B2 (en) 2003-10-16 2010-03-16 Kimberly-Clark Worldwide, Inc. Method for reducing odor using metal-modified particles
US7438875B2 (en) * 2003-10-16 2008-10-21 Kimberly-Clark Worldwide, Inc. Method for reducing odor using metal-modified silica particles
US7794737B2 (en) 2003-10-16 2010-09-14 Kimberly-Clark Worldwide, Inc. Odor absorbing extrudates
US7837663B2 (en) * 2003-10-16 2010-11-23 Kimberly-Clark Worldwide, Inc. Odor controlling article including a visual indicating device for monitoring odor absorption
US7879350B2 (en) * 2003-10-16 2011-02-01 Kimberly-Clark Worldwide, Inc. Method for reducing odor using colloidal nanoparticles
US7488520B2 (en) 2003-10-16 2009-02-10 Kimberly-Clark Worldwide, Inc. High surface area material blends for odor reduction, articles utilizing such blends and methods of using same
US7413550B2 (en) 2003-10-16 2008-08-19 Kimberly-Clark Worldwide, Inc. Visual indicating device for bad breath
WO2005062992A2 (fr) * 2003-12-23 2005-07-14 Abraxis Bioscience, Inc Derives substitues de melatonine, procede de fabrication et methodes d'utilisation
EP2520290B1 (fr) 2003-12-23 2014-12-10 Abraxis BioScience, LLC Analogues du propofol, procédé permettant de les préparer et méthodes permettant de les utiliser
US7700612B2 (en) * 2003-12-23 2010-04-20 Abraxis Bioscience, Llc Di-ester prodrugs of camptothecin, process for their preparation and their therapeutical applications
US20050186230A1 (en) * 2004-01-23 2005-08-25 Sd Pharmaceuticals, Inc. Elemene compositions containing liquid oil
US8957034B2 (en) * 2004-01-28 2015-02-17 Johns Hopkins University Drugs and gene carrier particles that rapidly move through mucous barriers
US20050196416A1 (en) * 2004-02-05 2005-09-08 Kipp James E. Dispersions prepared by use of self-stabilizing agents
US8784881B2 (en) * 2004-03-05 2014-07-22 Board Of Regents, The University Of Texas System Liposomal curcumin for treatment of diseases
US20080103213A1 (en) * 2004-03-05 2008-05-01 Board Of Regents, The University Of Texas System Liposomal curcumin for treatment of neurofibromatosis
WO2005102334A2 (fr) * 2004-04-13 2005-11-03 Alza Corporation Appareil et procede d'administration transdermique d'agents a base de fentanyle
CA2469339A1 (fr) * 2004-06-07 2005-12-07 Bernard Charles Sherman Gelules a liberation lente de chlorhydrate de propafenone
JP5362986B2 (ja) * 2004-06-23 2013-12-11 シンタ ファーマスーティカルズ コーポレイション 癌治療のためのビス（チオ‐ヒドラジドアミド）塩
JP4433918B2 (ja) * 2004-07-15 2010-03-17 コニカミノルタエムジー株式会社 画像形成方法
KR100578382B1 (ko) 2004-07-16 2006-05-11 나재운 항암제의 전달체용 수용성 키토산 나노입자 및 그 제조방법
KR100651728B1 (ko) * 2004-11-10 2006-12-06 한국전자통신연구원 정착기를 갖는 전자 소자용 화합물 및 이를 포함하는 전자소자와 이들의 제조 방법
US20060198891A1 (en) * 2004-11-29 2006-09-07 Francois Ravenelle Solid formulations of liquid biologically active agents
US20060159766A1 (en) * 2004-12-15 2006-07-20 Elan Pharma International Limited Nanoparticulate tacrolimus formulations
CA3054535A1 (fr) 2005-02-18 2006-08-24 Abraxis Bioscience, Llc Combinaisons et modes d'administration d'agents therapeutiques et de therapie combinee
US20070166388A1 (en) 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
WO2006089120A2 (fr) 2005-02-18 2006-08-24 Abraxis Bioscience, Inc Compositions, procedes d'utilisation et de preparation de 2,6-diisopropylphenol et d'analogues de ce dernier pour traiter une liaison ischemique
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
US8415388B2 (en) 2005-02-22 2013-04-09 Savvipharm Inc. Pharmaceutical compositions containing paclitaxel orotate
WO2006101972A2 (fr) * 2005-03-17 2006-09-28 Elan Pharma International Limited Compositions injectables de composes nanoparticulaires immunosuppresseurs
US7722581B2 (en) * 2005-04-11 2010-05-25 Gholam A. Peyman Crystalline lens drug delivery
US20060229585A1 (en) * 2005-04-11 2006-10-12 Minu, L.L.C. Drug delivery to the crystalline lens and other ocular structures
WO2006110811A1 (fr) 2005-04-12 2006-10-19 Elan Pharma International Limited Formules de nanoparticules de derives de quinazoline
BRPI0610219A2 (pt) * 2005-04-15 2010-06-08 Synta Pharmaceuticals Corp métodos de tratamento de um ser humano com cáncer e composição de farmacêutica
MX2007015183A (es) * 2005-06-14 2008-02-19 Baxter Int Formulaciones farmaceuticas para minimizar las interacciones farmaco-farmaco.
US20060280787A1 (en) * 2005-06-14 2006-12-14 Baxter International Inc. Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof
PL3311805T3 (pl) 2005-08-31 2020-07-27 Abraxis Bioscience, Llc Kompozycje zawierające słabo rozpuszczalne w wodzie środki farmaceutyczne i środki przeciwdrobnoustrojowe
KR101643416B1 (ko) * 2005-08-31 2016-07-27 아브락시스 바이오사이언스, 엘엘씨 증가된 안정성을 가진 수 난용성 약물의 조성물 및 제조방법
WO2007029898A1 (fr) * 2005-09-09 2007-03-15 Jae-Woon Nah Nanoparticule de chitosan soluble dans l'eau pour administrer un agent anticancereux et son procede de preparation
US20070098802A1 (en) * 2005-10-31 2007-05-03 Isaac Farr Organic nanoparticles and associated methods
US8882747B2 (en) * 2005-11-09 2014-11-11 The Invention Science Fund I, Llc Substance delivery system
JP5806444B2 (ja) * 2005-12-02 2015-11-10 ノバルティス アーゲー 免疫原性組成物で使用するためのナノ粒子
DE102005062440B4 (de) * 2005-12-27 2011-02-24 Lts Lohmann Therapie-Systeme Ag Proteinbasiertes Trägersystem zur Resistenzüberwindung von Tumorzellen
KR20130116954A (ko) 2005-12-28 2013-10-24 프레세니어스 카비 온콜로지 리미티드 나노 입자형 약제학적 조성물용으로 유용한, 생혼화성이고 비생분해성이며 비독성인 중합체
SE0600091L (sv) 2006-01-18 2007-04-17 Bows Pharmaceuticals Ag Förfarande för framställning av en dextranmatris för kontrollerad frisättning av insulin
AR054215A1 (es) 2006-01-20 2007-06-13 Eriochem Sa Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit
JP4974533B2 (ja) * 2006-01-30 2012-07-11 富士フイルム株式会社 ジスルフィド架橋したタンパク質ナノ粒子
US8367112B2 (en) * 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
US7458953B2 (en) * 2006-06-20 2008-12-02 Gholam A. Peyman Ocular drainage device
EP2054036B1 (fr) 2006-07-24 2019-12-18 Singh-Broemer and Company, Inc. Formulation de nanoparticules solides de substances pharmaceutiques insolubles dans l'eau avec mûrissement d'ostwald réduit
KR20090045354A (ko) 2006-08-21 2009-05-07 신타 파마슈티칼스 코프. 증식성 장애를 치료하기 위한 화합물
AU2007290490B2 (en) * 2006-08-31 2011-09-08 Synta Pharmaceuticals Corp. Combination with bis(thiohydrazide amides) for treating cancer
US20080280987A1 (en) * 2006-08-31 2008-11-13 Desai Neil P Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
DE602007012559D1 (de) * 2006-09-08 2011-03-31 Univ Johns Hopkins H die schleimhaut
US9498528B2 (en) * 2006-09-13 2016-11-22 Genzyme Corporation Treatment of multiple sclerosis (MS)
AR063704A1 (es) 2006-09-14 2009-02-11 Makhteshim Chem Works Ltd Nanoparticulas de pesticida obtenida obtenidas a partir de microemulsiones y nanoemulsiones
EP2061583B1 (fr) * 2006-09-14 2019-04-10 Yissum Research Development Company, of The Hebrew University of Jerusalem Nanoparticules organiques obtenues à partir de microémulsions par évaporation de solvant
US20080119820A1 (en) 2006-09-20 2008-05-22 Phan Phillip C Methods for Delivering Volatile Anesthetics for Regional Anesthesia and/or Pain Relief
JP5099545B2 (ja) * 2006-10-17 2012-12-19 公立大学法人大阪府立大学 化合物の溶解補助剤とそれを含む組成物
PT2091919E (pt) * 2006-11-15 2011-09-05 Abraxis Bioscience Llc Derivados de análogos de hidroquinona de geldamicina substituídos por 18-amino que apresentam atividade citotóxica para o tratamento de cancro.
US7799954B2 (en) * 2006-11-17 2010-09-21 Abraxis Bioscience, Llc Dicarbonyl derivatives and methods of use
US9675578B2 (en) 2006-12-14 2017-06-13 Abraxis Bioscience, Llc Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
WO2008076883A2 (fr) * 2006-12-15 2008-06-26 Abraxis Bioscience, Inc. Dérivés de triazine et leurs applications thérapeutiques
SI2481409T1 (sl) 2007-03-07 2018-09-28 Abraxis Bioscience, Llc Nanodelci, ki zajemajo rapamicin in albumin kot sredstvo proti raku
EP2146707A2 (fr) 2007-05-03 2010-01-27 Abraxis BioScience, LLC Procédés et compositions permettant le traitement de l'hypertension pulmonaire
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US8927019B2 (en) * 2007-06-01 2015-01-06 Abraxis Bioscience, Llc Methods and compositions for treating recurrent cancer
US8003621B2 (en) * 2007-09-14 2011-08-23 Nitto Denko Corporation Drug carriers
AR063111A1 (es) 2007-10-03 2008-12-30 Eriochem Sa Una formulacion farmaceutica de taxano
EP2244737B1 (fr) 2008-01-22 2019-04-10 The Board of Regents of The University of Texas System Compositions anesthésiques volatiles comprenant des solvants d'extraction pour une anesthésie régionale et/ou un soulagement de la douleur
AU2009234127B2 (en) * 2008-04-10 2015-04-30 Abraxis Bioscience, Llc Compositions of hydrophobic taxane derivatives and uses thereof
JP2011517683A (ja) * 2008-04-10 2011-06-16 アブラクシス バイオサイエンス， エルエルシー 疎水性タキサン誘導体の組成物およびその使用
EP2285443B1 (fr) 2008-05-01 2016-11-23 Bayer Intellectual Property GmbH Techniques et procédés pour l'adhésion d'un médicament à un ballonnet de cathéter
CN101658516B (zh) * 2008-08-26 2011-10-05 齐鲁制药有限公司 紫杉醇类药物组合物及其制备方法
NZ593343A (en) 2008-12-11 2013-04-26 Abraxis Bioscience Llc Combination cancer treatment conprising Abraxane and an inflamatory inhibitor
NZ595189A (en) 2009-03-13 2013-08-30 Abraxis Bioscience Llc Combination therapy with thiocolchicine derivatives
US7828996B1 (en) * 2009-03-27 2010-11-09 Abbott Cardiovascular Systems Inc. Method for the manufacture of stable, nano-sized particles
PL2419732T3 (pl) 2009-04-15 2020-05-18 Abraxis Bioscience, Llc Kompozycje nanocząstek wolnych od prionów i sposoby ich wytwarzania
WO2010144586A1 (fr) 2009-06-09 2010-12-16 Abraxis Bioscience, Llc Dérivés de l'isoquinoléine, de la quinoléine et de la quinazoléine servant d'inhibiteurs de signal hedgehog
US9078902B2 (en) 2009-06-09 2015-07-14 Nantbioscience, Inc. Triazine derivatives and their therapeutical applications
JP2012529517A (ja) 2009-06-09 2012-11-22 アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー ベンジル置換トリアジン誘導体類及びそれらの治療応用
CN101653611B (zh) * 2009-07-23 2012-05-09 复旦大学 一种白蛋白-阿霉素纳米制剂及其制备方法和应用
WO2011017835A1 (fr) * 2009-08-11 2011-02-17 Nanjing University Procédé de préparation de nanoparticules protéiques ou peptidiques pour l'administration de médicaments in vivo par déploiement et repliement
IN2012DN02018A (fr) 2009-08-25 2015-07-31 Abraxis Bioscience Llc
US10350364B2 (en) 2009-11-11 2019-07-16 Windgap Medical, Inc. Portable Drug Mixing and Delivery Device and Associated Methods
US9211283B2 (en) 2009-12-11 2015-12-15 Biolitec Pharma Marketing Ltd Nanoparticle carrier systems based on human serum albumin for photodynamic therapy
WO2011097149A2 (fr) * 2010-02-03 2011-08-11 Oncbiomune, L.L.C. Compositions contenant un taxane ou un taxoïde et une protéine
EP2898884B1 (fr) 2010-03-26 2018-05-09 Abraxis BioScience, LLC Procédés de traitement du carcinome hépatocellulaire
EP2552415B1 (fr) 2010-03-29 2016-09-07 Abraxis BioScience, LLC Méthodes de traitement du cancer
MX2012011155A (es) 2010-03-29 2012-12-05 Abraxis Bioscience Llc Metodos para mejorar suministros de farmacos y efectividad de agentes terapeuticos.
CA2795289A1 (fr) 2010-04-08 2011-10-13 Sanford-Burnham Medical Research Institute Methodes et compositions pour une administration amelioree de composes
NZ604029A (en) 2010-06-02 2015-07-31 Abraxis Bioscience Llc Methods of treating bladder cancer
NZ706745A (en) 2010-06-04 2017-01-27 Abraxis Bioscience Llc Methods of treatment of pancreatic cancer
US20140155344A1 (en) 2010-06-07 2014-06-05 Neil P. Desai Combination therapy methods for treating proliferative diseases
CN103202813B (zh) * 2010-08-09 2015-09-30 南京大学 一种制备用于体内递送药理活性物质的蛋白纳米粒的方法
CN103202812B (zh) * 2010-08-09 2015-10-28 南京大学 一种制备用于体内递送药理活性物质的蛋白纳米粒的方法
KR101223484B1 (ko) 2010-10-05 2013-01-17 한국과학기술연구원 사람 혈청 알부민-ｓｉＲＮＡ 나노입자 전달체
US8884027B2 (en) 2010-10-22 2014-11-11 University Of Rochester Melampomagnolide B derivatives as antileukemic and cytotoxic agents
US9808030B2 (en) 2011-02-11 2017-11-07 Grain Processing Corporation Salt composition
WO2012118778A1 (fr) 2011-02-28 2012-09-07 Sanford-Burnham Medical Research Institute Peptides car tronqués, procédés et compositions les utilisant
RU2475247C2 (ru) * 2011-03-05 2013-02-20 Республика Северная Осетия-Алания "Всероссийское общество изобретателей и рационализаторов" ("ВОИР") Способ профилактики несостоятельности кишечного анастомоза
CN102133190A (zh) * 2011-03-16 2011-07-27 中国药科大学 一种转铁蛋白纳米粒及其制备方法和用途
CO6540157A1 (es) 2011-04-15 2012-10-16 Univ Antioquia Proceso continuo para la elaboracion de nanoparticulas y nanoparticulas obtenidas mediante dicho proceso
SG194623A1 (en) 2011-04-28 2013-12-30 Abraxis Bioscience Llc Intravascular delivery of nanoparticle compositions and uses thereof
US10179801B2 (en) 2011-08-26 2019-01-15 Sanford-Burnham Medical Research Institute Truncated LYP-1 peptides and methods and compositions using truncated LYP-1 peptides
US9125884B2 (en) 2011-11-01 2015-09-08 Celgene Corporation Methods for treating cancers using oral formulations of cytidine analogs
WO2013085902A1 (fr) 2011-12-05 2013-06-13 The University Of Texas M.D. Procédés de polythérapie pour le traitement d'un cancer du sein inflammatoire
WO2013084207A1 (fr) 2011-12-07 2013-06-13 Universidade Do Minho Formulations micellaires protéiques et procédé de production correspondant
PL2790675T3 (pl) 2011-12-14 2019-12-31 Abraxis Bioscience, Llc Zastosowanie polimerowych rozczynników do liofilizacji lub zamrażania cząstek
RU2499991C2 (ru) * 2011-12-14 2013-11-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Северный государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации Способ дифференциальной диагностики типа гепаторенального синдрома алкогольного генеза
CA2871745C (fr) 2012-05-03 2023-01-24 Kala Pharmaceuticals, Inc. Nanoparticules pharmaceutiques presentant un transport muqueux ameliore
JP6360039B2 (ja) 2012-05-03 2018-07-18 カラ ファーマシューティカルズ インコーポレイテッド 複数の被覆された粒子を含む組成物、医薬組成物、医薬製剤、及び当該粒子の形成方法
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
BR112015001838B1 (pt) 2012-07-27 2022-10-25 Izumi Technology, Llc Composição de inibidor de efluxo
EP2914265A4 (fr) 2012-11-05 2016-04-13 Nant Holdings Ip Llc Dérivés indol-5-ole substitués et leurs applications thérapeutiques
BR112015010186A2 (pt) 2012-11-05 2017-07-11 Nant Holdings Ip Llc sulfonamida cíclica contendo derivados como inibidores da via de sinalização de hedgehog
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
EP2919903B1 (fr) * 2012-11-14 2020-07-22 W.R. Grace & CO. - CONN. Compositions contenant un matériau biologiquement actif et un oxyde inorganique non ordonné
JP5999765B2 (ja) * 2012-12-07 2016-09-28 バイオアバイラビリティ，インク． 栄養学的に使用するための高濃度自己マイクロエマルジョン化コエンザイムｑ１０調製物
PT106738B (pt) * 2013-01-09 2015-06-08 Hovione Farmaciencia Sa Método para o controlo do fenómeno de degradação difusional de ostwald (ostwald ripening) no processamento de partículas de um ingrediente farmacêutico
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
KR102148551B1 (ko) 2013-02-11 2020-08-26 아브락시스 바이오사이언스, 엘엘씨 흑색종을 치료하는 방법
ITBN20130001A1 (it) * 2013-02-19 2014-08-20 Prodal S C A R L Particelle biopolimeriche sub-micrometriche per la veicolazione di composti attivi in campo alimentare, farmaceutico e cosmetico e procedimento per la loro preparazioneparticelle biopolimeriche sub-micrometriche per la veicolazione di composti attivi
ES2804323T3 (es) 2013-03-12 2021-02-05 Abraxis Bioscience Llc Procedimientos de tratamiento de cáncer de pulmón
WO2014143613A1 (fr) 2013-03-13 2014-09-18 Abraxis Bioscience, Llc Méthodes de traitement de tumeur solide pédiatrique
MX2015011753A (es) 2013-03-14 2015-12-07 Abraxis Bioscience Llc Metodos para tratar cancer de vegija.
US9907910B2 (en) 2013-03-15 2018-03-06 Windgap Medical, Inc. Portable drug mixing and delivery device and associated methods
AU2014233069A1 (en) 2013-03-15 2015-09-24 Nantbioscience, Inc. Substituted indol-5-ol derivatives and their therapeutic applications
US10569017B2 (en) 2013-03-15 2020-02-25 Windgap Medical, Inc. Portable drug mixing and delivery device and associated methods
AU2014232211B2 (en) 2013-03-15 2017-05-25 Windgap Medical, Inc. Portable drug mixing and delivery system and method
KR101329646B1 (ko) * 2013-05-02 2013-11-14 주식회사 지니스 표적지향증폭형 항암나노입자 및 이의 제조방법
CN103393632B (zh) * 2013-07-26 2015-05-13 齐鲁制药(海南)有限公司 一种卡巴他赛药物组合物及其制备方法
CN104368007A (zh) * 2013-08-12 2015-02-25 于湛 可注射蛋白基花样结构载药微纳材料与内耳跨膜给药缓释制剂及其制备方法
KR20150047336A (ko) 2013-10-24 2015-05-04 삼성전자주식회사 나노입자, 이를 제조하는 방법, 및 이의 용도
CN104758942A (zh) * 2014-01-02 2015-07-08 国家纳米科学中心 基于蛋白质的药理活性物质组合物及其制备方法和应用
CN103705469B (zh) * 2014-01-03 2016-01-20 中国医学科学院药用植物研究所 一种和厚朴酚纳米粒及其制备方法
CN111803698B (zh) * 2014-02-14 2022-05-27 波士顿科学国际有限公司 具有治疗剂释放的快速降解栓塞颗粒
CN103861115B (zh) * 2014-03-18 2017-04-19 常州市第一人民医院 一种血红蛋白纳米粒及其制备方法
US20150359810A1 (en) 2014-06-17 2015-12-17 Celgene Corporation Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine
CN104434808A (zh) * 2014-07-03 2015-03-25 石药集团中奇制药技术（石家庄）有限公司 一种治疗性纳米粒子及其制备方法
US11116903B2 (en) 2014-08-18 2021-09-14 Windgap Medical, Inc Compression seal for use with a liquid component storage vial of an auto-injector
JP6456479B2 (ja) 2014-08-18 2019-01-23 ウィンドギャップ メディカル， インコーポレイテッド 携帯型薬剤混合及び送達装置並びに関連の方法
EP3241563B1 (fr) * 2014-12-05 2020-03-04 Kitayama, Yukiya Nanoparticule furtive in vivo
CN105727303B (zh) * 2014-12-12 2019-06-28 四川科伦药物研究院有限公司 一种高载卡巴他赛药物的白蛋白组合物及其制剂和制备方法
CN104490797A (zh) * 2014-12-22 2015-04-08 深圳海王药业有限公司 一种多相稳定的白蛋白结合型卡巴他塞
AU2015383881B2 (en) 2015-02-27 2021-01-28 Nantbioscience, Inc. Pyrimidine derivatives as kinase inhibitors and their therapeutical applications
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
US10527604B1 (en) * 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
CN106137969B (zh) * 2015-04-03 2020-05-15 四川科伦药物研究院有限公司 多西他赛白蛋白纳米粒药物组合物及其制备方法及应用
CN107921208B (zh) 2015-04-15 2020-12-25 温德加普医疗股份有限公司 与自动注射器组件一起使用的可拆卸致动顶盖
EP3294900B1 (fr) 2015-05-08 2021-09-22 Spectral Platforms, Inc. Utilisation de complexes non-covalents à base d'albumine dans la detection de microorganismes
US9763892B2 (en) 2015-06-01 2017-09-19 Autotelic Llc Immediate release phospholipid-coated therapeutic agent nanoparticles and related methods
WO2016210423A2 (fr) 2015-06-25 2016-12-29 Sanford Burnham Prebys Medical Discovery Institute Compositions à administrer dans des plaques athéroscléreuses, pour le traitement de ces plaques
WO2017004249A1 (fr) 2015-06-29 2017-01-05 Abraxis Bioscience, Llc Méthodes de traitement de tumeurs de cellules épithélioïdes
CN105055341A (zh) * 2015-08-13 2015-11-18 黑龙江泰华源生物技术有限责任公司 一种紫杉醇白蛋白结合型冻干制剂及其制备方法
CA2994300C (fr) 2015-08-13 2023-12-05 Windgap Medical, Inc. Dispositif de melange et d'injection a elements de sterilite
CN105816885A (zh) * 2016-04-15 2016-08-03 北京大学 一种药物白蛋白纳米粒的制备及其应用方法
BE1023653B1 (nl) * 2016-04-29 2017-06-07 Rousselot B.V. Eiwit gebaseerd excipient voor actieve farmaceutische stoffen
ES2925656T3 (es) * 2016-04-29 2022-10-19 Rousselot B V Excipiente basado en proteínas para principios farmacéuticos activos
CN105944109B (zh) * 2016-05-03 2019-06-11 四川大学 一种肾小球靶向的蛋白纳米颗粒药物组合物及其用途
CN106310221B (zh) * 2016-08-25 2019-11-22 齐鲁制药有限公司 一种含有卡非佐米的药物组合物及其制备方法
WO2018048958A1 (fr) * 2016-09-06 2018-03-15 Mayo Foundation For Medical Education And Research Compositions d'agents de liaison, de paclitaxel et d'albumine et leurs procédés d'utilisation et de production
KR20190068570A (ko) * 2016-10-10 2019-06-18 아브락시스 바이오사이언스, 엘엘씨 나노입자 제제, 및 그의 제조 및 사용 방법
ES2918976T3 (es) * 2016-11-30 2022-07-21 Dukebox Sp Z O O Un método para fabricar una solución de nanopartículas de ácido acetilsalicílico o diosmina o drotaverina
US11105747B2 (en) 2017-03-20 2021-08-31 Spectral Platforms, Inc. Spectroscopic methods to detect and characterize microorganisms
WO2018200393A1 (fr) * 2017-04-24 2018-11-01 Zy Therapeutics Inc. Composition pharmaceutique pour l'administration in vivo, procédé de préparation d'un principe pharmacologiquement actif sensiblement insoluble dans l'eau
CN107412783B (zh) 2017-04-28 2020-09-22 中国人民解放军军事医学科学院毒物药物研究所 一种包裹有难溶于水药物的蛋白质颗粒的制备方法
US11981752B2 (en) 2017-05-02 2024-05-14 Sanford Burnham Prebys Medical Discovery Institute Tumor associated monocyte/macrophage binding peptide and methods of use thereof
US10738033B2 (en) 2017-05-31 2020-08-11 Nantbio, Inc. Trk inhibition
US10800760B2 (en) 2017-05-31 2020-10-13 Nantbio, Inc. Trk inhibition
WO2019016692A1 (fr) * 2017-07-21 2019-01-24 Emcure Pharmaceuticals Limited Stabilisation de taille de particule de particules liées à une protéine et procédés associés
CN107412172A (zh) * 2017-08-04 2017-12-01 南京拉克森生物医药科技有限公司 一种紫杉醇白蛋白纳米混悬剂冻干粉及其制备工艺
US20200230068A1 (en) * 2017-08-25 2020-07-23 Nal Pharmaceutical Group Limited Compositions and methods of delivery of pharmacological agents
MX2020004836A (es) 2017-11-06 2020-10-16 Rapt Therapeutics Inc Agentes anticancerígenos.
BR112020018910A2 (pt) 2018-03-20 2020-12-29 Abraxis Bioscience, Llc Métodos de tratamento de transtorno do sistema nervoso central através da administração de nanopartículas de um unibidor de mtor e de uma albumina
CN108524452A (zh) * 2018-05-08 2018-09-14 辽宁大学 一种紫杉醇白蛋白纳米粒的制备方法和应用
TW202015659A (zh) 2018-05-22 2020-05-01 美商亞伯辛生物科學有限責任公司 用於治療肺高血壓之方法及組合物
CN113905722A (zh) * 2019-01-22 2022-01-07 锐创生物医药(香港)有限公司 白蛋白纳米颗粒、其制备方法和用途
WO2020161602A1 (fr) 2019-02-04 2020-08-13 University Of Tartu Peptides de liaison à la matrice extracellulaire bi-spécifiques et procédés d'utilisation de ceux-ci
US20220218789A1 (en) 2019-05-10 2022-07-14 Nant Holdings Ip, Llc Nogapendekin Alfa-Inbakicept For Immune Stimulant Therapies And Treatment Of Viral Infections
KR20220106758A (ko) 2019-10-28 2022-07-29 아브락시스 바이오사이언스, 엘엘씨 알부민 및 라파마이신의 제약 조성물
US11318189B1 (en) 2020-05-13 2022-05-03 Nantcell, Inc. IL-15 agonist drug combinations for immune therapy
CN114681408B (zh) * 2020-12-26 2023-06-23 四川汇宇制药股份有限公司 白蛋白结合型紫杉醇纳米粒的制备方法
EP4035655A1 (fr) * 2021-02-01 2022-08-03 Oxford University Innovation Limited Articules immunomodulatrices
EP4036580A1 (fr) * 2021-02-01 2022-08-03 Oxford University Innovation Limited Agent de cavitation chargé de médicaments
WO2024081674A1 (fr) 2022-10-11 2024-04-18 Aadi Bioscience, Inc. Polythérapies pour le traitement du cancer

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3959457A (en) * 1970-06-05 1976-05-25 Temple University Microparticulate material and method of making such material
GB1472793A (en) * 1974-03-28 1977-05-04 Ici Ltd Pharmaceutical compositions
US4073943A (en) * 1974-09-11 1978-02-14 Apoteksvarucentralen Vitrum Ab Method of enhancing the administration of pharmalogically active agents
US4247406A (en) * 1979-04-23 1981-01-27 Widder Kenneth J Intravascularly-administrable, magnetically-localizable biodegradable carrier
US4718433A (en) * 1983-01-27 1988-01-12 Feinstein Steven B Contrast agents for ultrasonic imaging
US4572203A (en) * 1983-01-27 1986-02-25 Feinstein Steven B Contact agents for ultrasonic imaging
US4622219A (en) * 1983-06-17 1986-11-11 Haynes Duncan H Method of inducing local anesthesia using microdroplets of a general anesthetic
ATE34407T1 (de) * 1983-06-22 1988-06-15 Stolle Res & Dev Eingekapselte zellen, verfahren zu deren herstellung und ihre verwendung.
US4671954A (en) * 1983-12-13 1987-06-09 University Of Florida Microspheres for incorporation of therapeutic substances and methods of preparation thereof
CA1215922A (fr) * 1984-05-25 1986-12-30 Connaught Laboratories Limited Microencapsulation de cellules et de tissus vivants
US4753788A (en) * 1985-01-31 1988-06-28 Vestar Research Inc. Method for preparing small vesicles using microemulsification
SE459005B (sv) * 1985-07-12 1989-05-29 Aake Rikard Lindahl Saett att framstaella sfaeriska polymerpartiklar
US5023271A (en) * 1985-08-13 1991-06-11 California Biotechnology Inc. Pharmaceutical microemulsions
WO1988001506A1 (fr) * 1986-08-28 1988-03-10 Thomas Ko Sai Ying Preparation microgranulaire servant dans l'administration de substances biologiquement actives dans les regions intestinales d'animaux
US4925678A (en) * 1987-04-01 1990-05-15 Ranney David F Endothelial envelopment drug carriers
IE59934B1 (en) * 1987-06-19 1994-05-04 Elan Corp Plc Liquid suspension for oral administration
SE8704158L (sv) * 1987-10-26 1989-04-27 Carbomatrix Ab C O Ulf Schroed Mikrosfaerer, foerfarande foer framstaellning daerav och anvaendning daerav
US4844882A (en) * 1987-12-29 1989-07-04 Molecular Biosystems, Inc. Concentrated stabilized microbubble-type ultrasonic imaging agent
FI101889B1 (fi) * 1988-08-24 1998-09-15 Allied Colloids Ltd Menetelmä partikkelikoostumuksen valmistamiseksi, joka sisältää polymeerimateriaalia sisältäviä partikkeleita
US5026559A (en) * 1989-04-03 1991-06-25 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
DE69005800T2 (de) * 1989-05-01 1994-05-19 Alkermes Inc Verfahren zur herstellung von kleinen partikeln von biologisch aktiven molekülen.
US5019400A (en) * 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
FR2651680B1 (fr) * 1989-09-14 1991-12-27 Medgenix Group Sa Nouveau procede de preparation de microparticules lipidiques.
FR2660556B1 (fr) * 1990-04-06 1994-09-16 Rhone Poulenc Sante Microspheres, leur procede de preparation et leur utilisation.
EP0524973B1 (fr) * 1990-04-17 1997-01-08 Isp Investments Inc. Preparation de microgouttelettes discretes d'une emulsion aqueuse stabilisee par polymerisation in situ d'un monomere vinylique soluble dans l'eau
US5059699A (en) * 1990-08-28 1991-10-22 Virginia Tech Intellectual Properties, Inc. Water soluble derivatives of taxol
US5110606A (en) * 1990-11-13 1992-05-05 Affinity Biotech, Inc. Non-aqueous microemulsions for drug delivery
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
FR2683159B1 (fr) * 1991-10-31 1994-02-25 Coletica Procede de fabrication de nanocapsules a paroi a base de proteines reticulees; nanocapsules ainsi obtenues et compositions cosmetiques, pharmaceutiques et alimentaires en comportant application.
EP0646000A4 (fr) * 1992-11-16 1997-05-02 Univ Mercer Compositions comprenant des anticorps de neutralisation microencapsules.
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US5362478A (en) * 1993-03-26 1994-11-08 Vivorx Pharmaceuticals, Inc. Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell
US5665382A (en) * 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of pharmaceutically active agents for in vivo delivery
EP0693924B2 (fr) * 1993-02-22 2008-04-09 Abraxis BioScience, Inc. Procedes d'administration (in vivo) de substances biologiques et compositions utilisees dans ces procedes
US5650156A (en) * 1993-02-22 1997-07-22 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of nutriceuticals and compositions useful therefor
GB9405593D0 (en) * 1994-03-22 1994-05-11 Zeneca Ltd Pharmaceutical compositions

Also Published As

Publication number Publication date
AU718753B2 (en) 2000-04-20
ES2323559T5 (es) 2012-12-03
BRPI9711856B8 (pt) 2021-05-25
CA2512487A1 (fr) 1998-04-09
EP0961612B2 (fr) 2012-08-01
BRPI9715297B8 (pt) 2021-05-25
NO328689B1 (no) 2010-04-26
EP0961612A1 (fr) 1999-12-08
NO991620L (no) 1999-06-01
CN1515244B (zh) 2013-08-07
ES2609853T3 (es) 2017-04-24
JP5117439B2 (ja) 2013-01-16
EP2286798A1 (fr) 2011-02-23
PT961612E (pt) 2009-06-17
CN1515244A (zh) 2004-07-28
ES2323559T3 (es) 2009-07-20
BRPI9711856B1 (pt) 2016-07-12
NL300417I1 (en) 2009-12-01
JP2009185042A (ja) 2009-08-20
HK1024866A1 (en) 2000-10-27
CN1157185C (zh) 2004-07-14
BR9711856A (pt) 2001-11-06
AU4592997A (en) 1998-04-24
NO991620D0 (no) 1999-04-06
WO1998014174A1 (fr) 1998-04-09
CA2267498C (fr) 2007-05-08
NZ335133A (en) 2000-12-22
DE69739348D1 (de) 2009-05-20
DK0961612T4 (da) 2012-10-08
EP1944019A3 (fr) 2008-07-30
EP0961612B1 (fr) 2009-04-08
US5916596A (en) 1999-06-29
CA2267498A1 (fr) 1998-04-09
ATE427739T1 (de) 2009-04-15
DE122009000065I1 (de) 2010-01-07
CA2512487C (fr) 2012-05-29
JP2001501931A (ja) 2001-02-13
DK0961612T3 (da) 2009-06-15
FR09C0050I2 (fr) 2012-06-22
EP1944019A2 (fr) 2008-07-16
JP4837809B2 (ja) 2011-12-14
LU91613I2 (fr) 2009-12-07
EP1944019B1 (fr) 2016-09-07
EP0961612A4 (fr) 2005-12-21
CN1237901A (zh) 1999-12-08
BRPI9715297B1 (pt) 2016-07-12

Similar Documents

Publication Publication Date Title
FR09C0050I1 (fr)
MX337149B (es) Nuevas formulaciones de agentes farmacologicos, metodos para su preparacion y metodos para el uso de los mismos.
EP2014286A3 (fr) Particules de epothilone sans cremophor recouvertes de protein pour le traitement du cancer
WO2000071079A3 (fr) Agents a stabilisation proteinique actifs pharmacologiquement; procedes de fabrication et methodes d'utilisation
Kuo et al. Inhibition of human brain malignant glioblastoma cells using carmustine-loaded catanionic solid lipid nanoparticles with surface anti-epithelial growth factor receptor
Zheng et al. Transferrin-conjugated lipid-coated PLGA nanoparticles for targeted delivery of aromatase inhibitor 7α-APTADD to breast cancer cells
BG105379A (en) Pharmaceutical compositions for the treatment of acute disorders
CA2372576A1 (fr) Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
BR0016012A (pt) Implante farmacêutico contendo componentes de liberação imediata e de liberação prolongada, além de processo de administração
GB9300875D0 (en) Nanocapsule containing pharmaceutical compositions
HK1006153A1 (en) Vehicle systems for use in cosmetic compositions
CA2338358A1 (fr) Composes permettant de delivrer des agents actifs et compositions a base de ces composes
ATE186638T1 (de) Wirkstoffe und wasserlösliche polymeren enthaltende zubereitungen in form fester teilchen
HK1043548A1 (en) Methods for preparing coated drug particles and pharmaceutical formulations thereof
ATE124864T1 (de) Die wirkstoffabgabe steuerndes überzugsmaterial für lang wirksame formulierungen.
CN106492221A (zh) 一种还原响应性纳米氧化石墨烯包覆载药介孔二氧化硅纳米粒子及其制备方法
HK1038310A1 (en) Compositions and methods for treating intracellular infections.
SG165156A1 (en) Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
NO20011670L (no) Preparat for parenteral administrering av aktive forbindelser
WO2024134511A3 (fr) Composition de nanoparticules lipidiques
JPS63280005A (ja) 脂溶性ビタミン含有粉末化粧料
남기영 Antibacterial activity and characterization of tissue conditioner containing silver-chitosan nanocomplex